Cargando…

Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin

This study aimed to clarify that organic anion transporters (OATs) mediate the drug–drug interaction (DDI) between imipenem and cilastatin. After co-administration with imipenem, the plasma concentrations and the plasma concentration-time curve (AUC) of cilastatin were significantly increased, while...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yanna, Huo, Xiaokui, Wang, Changyuan, Meng, Qiang, Liu, Zhihao, Sun, Huijun, Tan, Aiping, Ma, Xiaodong, Peng, Jinyong, Liu, Kexin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shenyang Pharmaceutical University 2020
Materias:	Research article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193450/ https://www.ncbi.nlm.nih.gov/pubmed/32373203 http://dx.doi.org/10.1016/j.ajps.2018.11.006

Ejemplares similares

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
por: Huo, Xiaokui, et al.
Publicado: (2019)

Piperacillin enhances the inhibitory effect of tazobactam on β-lactamase through inhibition of organic anion transporter 1/3 in rats
por: Yang, Shilei, et al.
Publicado: (2019)

JBP485, A Dual Inhibitor of Organic Anion Transporters (OATs) and Renal Dehydropeptidase-I (DHP-I), Protects Against Imipenem-Induced Nephrotoxicity
por: Wang, Chong, et al.
Publicado: (2022)

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

Imipenem-cilastatin-induced psychosis: a case report
por: Ninan, Jacob, et al.
Publicado: (2016)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin
por: Agudelo, Maria, et al.
Publicado: (2019)

Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia
por: Choi, Jun Yong, et al.
Publicado: (2006)

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021)

Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: More than just down-regulation of MDR1
por: Wang, Changyuan, et al.
Publicado: (2016)

Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin
por: Xue, Chaojun, et al.
Publicado: (2016)

Metabolic alkalosis: A less appreciated side effect of Imipenem-cilastatin use
por: Panda, Pragyan Swagatika, et al.
Publicado: (2013)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
por: Kabbara, Wissam K, et al.
Publicado: (2015)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
por: Shaaban, Mona I., et al.
Publicado: (2017)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
por: Arima, Takahiro, et al.
Publicado: (2022)

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
por: Rebold, Nicholas, et al.
Publicado: (2021)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Naik, Jaesh, et al.
Publicado: (2023)

1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Kaye, Keith, et al.
Publicado: (2018)

Metabolic alkalosis: A less appreciated side-effect of imipenem cilastatin use-author's reply
por: Panda, P. S., et al.
Publicado: (2014)

Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections: A Meta-analysis
por: Sahra, Syeda, et al.
Publicado: (2021)

Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in ICU: an open randomised multicentre study
por: Verwaest on behalf of the Belgiun Multicentre study group, C
Publicado: (1997)

Imipenem-Cilastatin versus Sulbactam-Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients
por: ÖZYILKAN, Özgür, et al.
Publicado: (1999)

Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin
por: Chen, Chang-Hua, et al.
Publicado: (2017)

Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections
por: Vaziri, Ali Zaman, et al.
Publicado: (2021)

Transcatheter arterial embolization using imipenem/cilastatin sodium and microspheres for traumatic pseudoaneurysm: A case report
por: Hirano, Takaki, et al.
Publicado: (2022)

Increased antibiofilm and growth inhibitory effect of Imipenem/Cilastatin nanoliposomes against clinical Pseudomonas aeruginosa isolates
por: Milani, Faezeh, et al.
Publicado: (2023)

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in Pseudomonas aeruginosa Isolates from Sepsis
por: de Sousa, Telma, et al.
Publicado: (2023)

Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
por: Yang, Joe, et al.
Publicado: (2022)

A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia
por: Kollef, Marin H, et al.
Publicado: (2012)

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
por: Rizk, Matthew L., et al.
Publicado: (2018)

Reply: Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections
por: Jahangir, Abdullah, et al.
Publicado: (2021)

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
por: Patel, Munjal, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
por: Rhee, Elizabeth G., et al.
Publicado: (2018)

Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
por: Yang, Joe, et al.
Publicado: (2022)

1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model
por: Chen, Iris H, et al.
Publicado: (2020)

1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC)
por: Fratoni, Andrew J, et al.
Publicado: (2021)

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: a single-center retrospective study
por: Hiraki, Sakiko, et al.
Publicado: (2023)

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial
por: Chen, Zhangjing, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_h0c6slertkbk77vcb3bot0524s